The National Comprehensive Cancer Network (NCCN) published new guidelines for pediatric soft tissue sarcoma (STS), growing the NCCN’s library of guidelines to now cover 91 topics in cancer care. 1 ...
3don MSN
Promising new therapy developed for most common form of bone cancer in children and young adults
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
A mom of a 2-year-old boy diagnosed with cancer is urging parents to be persistent with doctors if they worry something is wrong with their child. Alison Miller's son, Atlas, was 8 months old and just ...
Kaposi's sarcoma (KS) is a low-grade vascular neoplasm mediated by the human herpesvirus-8. Only 1 clinical subtype, the endemic/African subtype, commonly affects the pediatric population. Although ...
In our three-part series -- Fighting For Hope: Pediatric Cancer's Funding Crisis -- 3News' Maureen Kyle follows the journey of young patients and their families as they navigate pediatric cancer. This ...
Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and Adolescents Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in ...
Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...
Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma Whole-Genome Profiling of Pediatric Diffuse ...
CHICAGO – An artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone, according to results presented at the American Association for ...
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...
CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results